ARTICLE | Company News
RaQualia, Durata Therapeutics deal
August 3, 2015 7:00 AM UTC
RaQualia elected to regain Japanese rights to dalbavancin from Allergan plc (NYSE:AGN, Dublin, Ireland). In December 2010, RaQualia granted Durata Japanese rights to the second-generation glycopeptid...